Mindset Pharma engages InterVivo Solutions for Initial Drug Analysis
February 10, 2020
Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has executed a Master Laboratory Services Agreement (the “MLSA”) with InterVivo Solutions Inc. (“InterVivo”). Based in Fergus, Ontario, InterVivo is a specialty preclinical contract research organization which develops and provides translational animal models and transformative research services in an effort to improve the clinical success of new therapeutics, particularly in central nervous system indications. Under the terms of the MLSA, InterVivo will provide initial pharmacokinetics (PK) work to Mindset, providing the basis for interpreting the dose-related efficacy, safety and toxicological effects of the Company’s patent-pending compounds. InterVivo will also support early screening paradigms designed to identify and select new chemical entities with favourable PK properties, to help further characterize leads to aid the transition to successful clinical trials. Mindset is excited to work with InterVivo and intends on being in their laboratory facilities in Q2 2020 with its first patent-pending psychedelic compounds. About InterVivo Solutions InterVivo is a Canadian-based preclinical contract research organization with a mission to develop and provide translational animal models and transformative research services in an effort to improve the clinical success of new therapeutics, particularly in Central Nervous System indications. In addition to drug metabolism, exploratory safety and pharmacokinetics screening, InterVivo provides rodent models of cognitive dysfunction, obesity, abuse liability, pain and epilepsy, and Parkinson’s disease. InterVivo also provides a natural aging canine model of human diseases with a particular emphasis on Alzheimer’s disease progression, osteoarthritis, obesity, cancer and metabolic disorders.
About Mindset Pharma
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.